Owner Scorecard


← All companies ← GEO Manual GES → ← FBRX Pharmaceuticals GLAS →

GERN, Geron Corporation

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer.

RYTELO is the first and only telomerase inhibitor approved by the EC, and the marketing authorization applies to all 27 European Union member states, and Iceland, Norway and Liechtenstein.

Latest annual: FY2025 10-K
GERN · Geron Corporation
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$237K
−60.2% YoY · −26% 5-yr CAGR
Vital signs · FY2025
Cash & investments $170M
Cash burn · annual $111M
Runway 1.5 yrs

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −8184% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 664% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −30%, above 15% in 0 of 10 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2014–2023

realized figures from each filing · older years to the left
2014’142015’152016’162017’172018’182019’192020’202021’212022’222023’23
Income statement
$1M$36M$6M$1M$1M$460K$253K$1M$596K$237KRevenueRevenue
n/m49%304%n/mn/mn/mn/mn/mn/mn/mSG&A / revenueSG&A/rev
n/m49%293%n/mn/mn/mn/mn/mn/mn/mR&D / revenueR&D/rev
($36M)($559K)($31M)($29M)($31M)($73M)($77M)($114M)($139M)($194M)Operating incomeOp. inc.
n/m−1.5%−497.3%n/mn/mn/mn/mn/mn/mn/mOperating marginOp. mgn
($36M)$46K($30M)($28M)($27M)($69M)($76M)($116M)($142M)($184M)Net incomeNet inc.
Cash flow & returns
$9M($24M)($18M)($21M)($21M)($44M)($67M)($96M)($127M)($168M)Operating cash flowOp. cash
$56K$81K$76K$59K$64K$158K$215K$288K$442KDepreciationDeprec.
$37M($33M)$3M($860K)($419K)$19M$2M$12M$6M($3M)Working capital & otherWC & other
$131K$90K$57K$16K$413K$401K$207K$431K$830KCapexCapex
11.4%0.2%0.9%1.5%89.8%158.5%14.9%72.3%350.2%Capex / revenueCapex/rev
$9M($24M)($18M)($21M)($44M)($67M)($96M)($128M)($169M)Owner earningsOwner earn.
799.6%−66.8%−299.0%n/mn/mn/mn/mn/mn/mOwner earnings marginOE mgn
$9M($24M)($18M)($21M)($44M)($67M)($96M)($128M)($169M)Free cash flowFCF
799.6%−66.8%−299.0%n/mn/mn/mn/mn/mn/mFree cash flow marginFCF mgn
-33%-0%-22%-26%-15%-47%-27%-64%-147%-59%ROICROIC
-27%0%-24%-27%-15%-51%-36%-92%-177%-74%Return on equityROE
−27%0%−24%−27%−15%−51%−36%−92%−177%−74%Retained to equityRetained/eq
Balance sheet
$170M$146M$129M$109M$11M$14M$10M$35M$57M$70MCash & investmentsCash+inv
$1M$160K$225K$503K$982K$1M$7M$7M$10M$6MAccounts payablePayables
$153M$116M$116M$96M$166M$142M$200M$187M$180M$341MCurrent assetsCur. assets
$42M$7M$8M$7M$8M$28M$31M$46M$77M$108MCurrent liabilitiesCur. liab.
3.7×17.5×14.8×14.7×22.0×5.0×6.5×4.1×2.4×3.2×Current ratioCurr. ratio
$173M$149M$130M$110M$185M$166M$271M$226M$191M$394MTotal assetsAssets
$24M$50M$51M$82MTotal debtDebt
$14M$15M($6M)$12MNet debt / (cash)Net debt
-101.2×-30.5×-20.1×-23.3×Interest coverageInt. cov.
$131M$142M$122M$104M$178M$135M$211M$126M$80M$248MShareholders’ equityEquity
664.2%23.1%133.8%764.7%597.4%n/mn/m580.0%n/mn/mStock comp / revenueSBC/rev
Per share
154M163M159M159M177M190M271M328M381M571MShares out (diluted)Shares
$0.01$0.22$0.04$0.01$0.01$0.00$0.00$0.00$0.00$0.00Revenue / shareRev/sh
$-0.23$0.00$-0.19$-0.18$-0.15$-0.36$-0.28$-0.35$-0.37$-0.32EPS (diluted)EPS
$0.06$-0.15$-0.12$-0.12$-0.23$-0.25$-0.29$-0.34$-0.30Owner earnings / shareOE/sh
$0.06$-0.15$-0.12$-0.12$-0.23$-0.25$-0.29$-0.34$-0.30Free cash flow / shareFCF/sh
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00Cap. spending / shareCapex/sh
$0.85$0.87$0.77$0.65$1.01$0.71$0.78$0.39$0.21$0.43Book value / shareBVPS

The diluted share count moved ×1.43 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.5 into 2023 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share−27.5%/yr−41.5%/yr
Capital spending / share+6.1%/yr+74.2%/yr
Book value / share−7.2%/yr−15.5%/yr

The record, charted

FY2014–2023

Each measure over its full record; the current point and the worst year marked.

Share count
571Mpeak FY2023
ROIC
−59%low FY2022

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

($169M)owner earningsvs.($184M)net incomelow FY2023

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2023 the business turned a $184M loss into ($169M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2023FY2022FY2021FY2020FY2019
Reported net income($184M)($142M)($116M)($76M)($69M)
Depreciation & amortizationnon-cash charge added back+$442K+$288K+$215K+$158K+$64K
Stock-based compensationreal costnon-cash, but a real cost+$19M+$8M+$8M+$7M+$6M
Working capital & othertiming of cash in and out, other non-cash items−$3M+$6M+$12M+$2M+$19M
Cash from operations($168M)($127M)($96M)($67M)($44M)
Capital expenditurecash put back in to keep running and to grow−$830K−$431K−$207K−$401K−$413K
Owner earnings($169M)($128M)($96M)($67M)($44M)
Owner-earnings marginowner earnings ÷ revenue-71128%-21445%-6875%-26503%-9618%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $19M), owner earnings is nearer ($187M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →
Material weakness in financial controls
“As described further below, we identified a material weakness in our internal control over financial reporting that existed as of September 30, 2025, which we remediated as of December 31, 2025.”

The figures below are only as sound as the controls that produced them. read the note →

Will it survive?

  • Does not cover its interest
    Operating income ($69M) ÷ interest expense $33M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net debt against an operating loss
    Cash $78M + ST investments $78M − debt $166M
    What this means

    Netting $156M of cash and short-term investments against $166M of debt leaves $11M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. It also holds $14M in longer-dated marketable securities; counting those, it sits at net cash of $4M. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    10-yr median, range -147%–-0%; -17% latest = NOPAT ($54M) ÷ invested capital $315M
    Industry peers: median -66%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran -17% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Consumes cash through the cycle
    9-yr median margin, range -71128%–800%; latest ($112M) = operating cash ($111M) − maintenance capex $680K
    Industry peers: median -6338%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -47138% of revenue this year, a -6875% median across 9 years. Treating stock comp as the real expense it is (less $27M of SBC) leaves ($138M).

  • Loss, and burning cash
    Net income ($84M) · cash from operations ($111M)

    In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.

    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • No surplus to allocate
    What this means

    The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.

  • Investing or harvesting? 1.43×
    Expanding
    Capex $680K ÷ depreciation $474K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 2 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $237K
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 4.66×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $166M vs $409M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 9 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.23/share (latest year $-0.13), the averaged base the calculator's gate runs on, and book value is $0.35/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2014–2023

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 1 of 10
    What this means

    Lost money in 9 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 4 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −1216% → −37754% (3-yr avg ends)

    In the filing’s words Input costs rose and the filing says it could not fully pass them on — which is where this margin compressed.

    What this means

    Through the cycle the operating margin slipped — about −1216% early to −37754% lately, median −8184% — competition or costs are biting in.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2023 · −81832.9% op. margin
    What this means

    Operations went underwater in 2023, understand why before trusting the good years.

  • How management talks about it Promotional
    What this means

    The returns have faded, yet the filing reaches for a promoter’s vocabulary — world-class, best-in-class, disruptive — more than an owner’s. When the words sell harder than the results deliver, the gap is the thing to weigh.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing A competitive risk, new this year

Its FY2025 10-K names artificial intelligence as a competitive threat, in language that was not in the prior year's filing.

“If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$499M
  • Cash & short-term investments$211M
  • Receivables$42M
  • Inventory$133M
  • Other current assets$113M
Current liabilities$74M
  • Accounts payable$13M
  • Other current liabilities$61M
Current ratio6.78×all current assets ÷ what's due · Graham looked for 2×
Quick ratio4.96×stricter: inventory excluded
Cash ratio2.86×strictest: cash alone against what's due
Working capital$425Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+30.9%the freshest read on whether the business is still growing
Current ratio, recent quarters3.6× → 6.8×
Deeper floors
Tangible book value$229Mequity stripped of goodwill & intangibles
Net current asset value$194MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$122M$2M of it operating leases
Deferred revenue$35Mcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid.

  • Insider ownership1.7%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio35:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$27M

    The slice of the business handed to employees in shares this year, 11249% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
SGMTSagimet Biosciences Inc. Series A$2M-2844.5%-59%
CLDXCelldex Therapeutics Inc.$2M96%-1799.4%-38%-1461%
PLURPluri Inc.$1M49%-8420.8%-68%-6856%
DMACDiaMedica Therapeutics Inc.$500K-6879.4%-67%-5820%
SVRASavara Inc.$257K-6852.8%-64%-5624%
GERNGeron Corporation$237K-5666.5%-30%-6875%
CADLCandel Therapeutics Inc.$125K-20580.8%-17960%
FBRXForte Biosciences Inc.$36K-37981.2%-545%-34751%
Group median-6866.1%-64%-6856%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Geron Corporation is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered−13%/yr’18→’23

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−47138%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Geron Corporation (GERN), the owner's record," https://ownerscorecard.com/c/GERN, data as of 2026-07-09.

Manual order: ← GEO its page in the Manual GES →

Industry order: ← FBRX the Pharmaceuticals chapter GLAS →